FDA clears first dual-lead nerve stimulator for pain relief | Digital Science

The FDA granted clearance to SPR Therapeutics' single- and dual-lead peripheral nerve stimulation devices as minimally invasive, non-opioid alternatives, implanted for up to 60 days for relieving acute and chronic , including postoperative and post-traumatic pain.

The Cleveland-based company's Sprint system includes the single-lead Endura and the industry's first dual-lead device, Extensa, which allows physicians to deliver therapy to two nerve targets in patients with broader injuries.

Percutaneous leads are placed by a physician in the back or extremities during an outpatient procedure without surgical incisions or anesthesia, while a single, wearable electronic pulse generator features rechargeable batteries and a Bluetooth-enabled remote control.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

“Our Sprint PNS platform is designed to deliver the least invasive and most user-friendly PNS therapy experience for physicians and their patients,” SPR's founder, president and CEO, Maria Bennett, said in a statement.

SPR Sprint
The Sprint system's wearable
generator and remote. (Image: SPR)

All of the device components are removed at the end of the treatment period, compared to other PNS systems that may require a permanent implant. SPR previously obtained a 510(k) clearance in June 2016 for a 30-day regimen.

RELATED: SPR bags $25M to market nonopioid pain- device

“With the ease of use and dual lead capabilities we've built into the SPRINT System we look forward to advancing the early use of neurostimulation as a non-opioid alternative for more patients while we continue to generate data that demonstrate significant and sustained pain relief following our 60-day therapy,” Bennett said.

According to SPR, preliminary results from a federally funded study of the system in chronic post-amputation pain showed significant reductions of at least 50% among two-thirds of patients after 8 weeks of treatment. In addition, long-term pain relief was reported by four of five patients who completed a 12-month study, most of which were implanted with dual leads in the hip and thigh.

You might also like

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More